Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00101127 · ClinicalTrials.gov registry record · Phase 2

Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

A Phase 2 study of Sarcoma, sponsored by Gynecologic Oncology Group.

Completed
Registry status
Phase 2
Development phase
20
Study locations

NCT00101127: Completed Phase 2 study of Sarcoma, sponsored by Gynecologic Oncology Group.

NCT00101127 is a Phase 2 study of Sarcoma that has completed, run by Gynecologic Oncology Group. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00101127, a Phase 2 study of Sarcoma, has completed, sponsored by Gynecologic Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF and pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving docetaxel and gemcitabine together with G-CSF or pegfilgrastim may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel and gemcitabine together with G-CSF or pegfilgrastim works in treating patients with advanced, persistent, or recurrent uterine leiomyosarcoma.

Conditions Studied

Sarcoma

Interventions

  • DRUG docetaxel
  • BIOLOGICAL filgrastim
  • BIOLOGICAL pegfilgrastim
  • DRUG gemcitabine hydrochloride

Study Locations (20)

Illinois

  • Rush-Copley Cancer Care Center - Aurora
  • Rush University Medical Center - Chicago
  • University of Chicago Cancer Research Center - Chicago
  • Hinsdale Hematology Oncology Associates - Hinsdale
  • Joliet Oncology-Hematology Associates, Limited - West - Joliet
  • Carle Cancer Center at Carle Foundation Hospital - Urbana
  • CCOP - Carle Cancer Center - Urbana

Georgia

  • MBCCOP-Medical College of Georgia Cancer Center - Augusta
  • Medical Center of Central Georgia - Macon
  • Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center - Savannah

California

  • Kaiser Permanente Medical Center - Los Angeles - Los Angeles
  • Jonsson Comprehensive Cancer Center at UCLA - Los Angeles

Connecticut

  • Helen and Harry Gray Cancer Center at Hartford Hospital - Hartford
  • New Britain General Hospital - New Britain

Delaware

  • CCOP - Christiana Care Health Services - Newark

Indiana

  • Saint Anthony Memorial Health Centers - Michigan City

Iowa

  • Holden Comprehensive Cancer Center at University of Iowa - Iowa City

Louisiana

  • Woman's Hospital - Baton Rouge

Trial Details

FieldValue
Start Date 2003-12
Phase Phase 2
Gynecologic Oncology Group

154 total trials

What the finished NCT00101127 record still lists

NCT00101127 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which docetaxel is the first listed.

NCT00101127 names 20 study sites across 10 states, led by Illinois, Georgia, California.

Frequently Asked Questions

What is clinical trial NCT00101127 about?

NCT00101127 is a clinical study titled "Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma". RATIONALE: Drugs used in chemotherapy, such as docetaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF and pegfilgrastim, may increase the number of immune cells foun...

What is the current status of trial NCT00101127?

This trial is currently completed. It is a Phase 2 study. The study started on 2003-12.

What conditions does trial NCT00101127 study?

This clinical trial studies the following conditions: Sarcoma.

What interventions are being tested in trial NCT00101127?

The interventions under investigation include: docetaxel (DRUG), filgrastim (BIOLOGICAL), pegfilgrastim (BIOLOGICAL), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00101127?

This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00101127 being conducted?

This trial has 20 study locations across California, Connecticut, Delaware, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00101127, the US trial registry maintained by the National Library of Medicine. NCT00101127 (unsized enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.